Integration of apolipoprotein B into the SCORE2 framework: implications for cardiovascular risk prediction

被引:0
|
作者
Wong, Wen Kai [1 ,2 ,3 ]
Takeuchi, Fumihiko [1 ,4 ,5 ]
Thao, Le Thi Phuong [6 ]
Nicholls, Stephen J. [7 ,8 ]
Chew, Derek P. [7 ,8 ]
Peter, Karlheinz [1 ,2 ]
机构
[1] Univ Melbourne, Fac Med Dent & Hlth Sci, Grattan St, Parkville, Vic 3010, Australia
[2] Baker Heart & Diabet Inst, Atherothrombosis & Vasc Biol Lab, 75 Commercial Rd, Melbourne, Vic 3004, Australia
[3] Imperial Coll London, Fac Med, London, England
[4] Baker Heart & Diabet Inst, Syst Genom Lab, Melbourne, Australia
[5] Baker Heart & Diabet Inst, Cambridge Baker Syst Genom Initiat, Melbourne, Australia
[6] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Australia
[7] Monash Univ, Victorian Heart Inst, Melbourne, Australia
[8] Monash Hlth, Victorian Heart Hosp, Melbourne, Australia
基金
英国医学研究理事会;
关键词
Apolipoprotein B (ApoB); Systematic Coronary Risk Evaluation 2 (SCORE2); Cardiovascular risk prediction; UK Biobank; CORONARY-HEART-DISEASE; MYOCARDIAL-INFARCTION; LDL-CHOLESTEROL; I RATIO; A-I; PREVENTION; GUIDELINES; MANAGEMENT; SOCIETY; MARKERS;
D O I
10.1093/eurjpc/zwaf039
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To evaluate whether integrating Apolipoprotein B (ApoB) into the Systematic Coronary Risk Evaluation 2 (SCORE2) cardiovascular risk prediction framework improves its predictive accuracy and clinical applicability within the UK Biobank population. Methods and results A 10-year prospective cohort study was conducted with 448 303 UK Biobank participants eligible for SCORE2 calculation. Three approaches were employed: (i) threshold analysis to determine the optimal ApoB cutoff for cardiovascular disease (CVD) risk prediction using Youden's Index, (ii) assessment of the synergistic effect of SCORE2 and ApoB through concordant and discordant classifications, and (iii) recalibration of the SCORE2 model by incorporating ApoB as an additional predictor. Each 0.2 g/L increase in ApoB was associated with an increased subdistribution hazard for CVD events [subdistribution hazard ratio (SHR): 1.13; 95% CI: 1.11-1.14, P < 0.001], accounting for non-cardiovascular death as a competing risk. Threshold analysis identified an optimal ApoB cutoff at 1.18 g/L; however, it demonstrated limited discriminatory performance (area under the curve 0.54), with low sensitivity (32.4%), and moderate specificity (74.4%). Individuals with both low ApoB (<1.18 g/L) and low SCORE2 risk (<5%) had a lower CVD incidence rate (232.51 per 100 000 person-years) compared with those identified as low risk by SCORE2 alone (253.69 per 100 000 person-years). Integration of ApoB into the SCORE2 model did not significantly improve the model discrimination, calibration, and net reclassification improvement. Conclusion Apolipoprotein B exhibited a dose-response relationship with cardiovascular risk but had limited standalone predictive utility within the UK Biobank population. However, combining ApoB with SCORE2 thresholds improved the identification of low-risk individuals, suggesting a complementary role for ApoB in refining cardiovascular risk stratification.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] The new SCORE2 risk prediction algorithms and the growing challenge of risk factors not captured by traditional risk scores
    Crea, Filippo
    EUROPEAN HEART JOURNAL, 2021, 42 (25) : 2403 - 2407
  • [22] Cardiovascular Risk in Systemic Lupus Erythematosus: Carotid Ultrasonography Is Useful for the Re-stratification of Cardiovascular Risk Determined by Score2
    Corrales Selaya, Cristina
    Bejerano, Carmen
    Secada Gomez, Carmen
    Portilla-Gonzalez, Virginia
    Blanco-Alonso, Ricardo
    Martinez Taboada, Victor Manuel
    Riancho, Leyre
    Corrales-Martinez, Alfonso
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 3031 - 3033
  • [23] Association between Cardiovascular Risk Assessment by SCORE2 and Diverticulosis: A Cross-Sectional Analysis
    Voelkerer, Andreas
    Wernly, Sarah
    Semmler, Georg
    Flamm, Maria
    Radzikowski, Konrad
    Datz, Leonora
    Goetz, Nikolaus
    Hofer, Hannah
    Aigner, Elmar
    Datz, Christian
    Wernly, Bernhard
    JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (08):
  • [24] Adding ethnicity to cardiovascular risk prediction: External validation and model updating of SCORE2 using data from the HELIUS population cohort
    van Apeldoorn, Joshua A. N.
    Hageman, Steven H. J.
    Harskamp, Ralf E.
    Agyemang, Charles
    van den Born, Bert-Jan H.
    van Dalen, Jan Willem
    Galenkamp, Henrike
    Hoevenaar-Blom, Marieke P.
    Richard, Edo
    van Valkengoed, Irene G. M.
    Visseren, Frank L. J.
    Dorresteijn, Jannick A. N.
    van Charante, Eric P. Moll
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2024, 417
  • [25] Prevalence and cardiovascular risk assessment in HIV patients: comparison between SCORE2 and REGICOR scales
    Diaz Martin, Estefania
    Cachapa Viera, Ines
    Calzado Isbert, Sonia
    Navarro Saez, Maria Del Carmen
    Pedrosa Aragon, Marc
    Navarro Vilasaro, Marta
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 269 - 269
  • [26] THE UPDATED CARDIOVASCULAR RISK ESTIMATION SCALE SCORE2 DOES NOT IMPROVE THE PRECISION IN PREDICTING CARDIOVASCULAR EVENTS IN PATIENTS WITH GOUT
    Lopez Gonzalez, M. D. C.
    Tovar-Sugranes, E.
    Rodriguez Alvear, C.
    Perea Martinez, E.
    Monzo, M.
    Aviles, A.
    Andres, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 317 - 317
  • [27] Cardiovascular risk assessment using SCORE2 in a population with hypertension -- The reality at a primary health care unit
    Santos, Sara Pereira
    Guedes, Sara
    Pesqueira, Ricardo
    Carvalho, Ana M.
    Correia, Patricia
    Ribeiro, Isabel Lourenco
    Teixeira, angela M.
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2024, 43 (11) : 601 - 610
  • [28] Performance of SCORE2 and SCORE2-OP risk algorithms in a Cypriot cohort
    Nicolaides, Andrew N.
    Griffin, Maura
    Panayiotou, Andrie G.
    Tyllis, Theodosis
    Bond, Dawn
    Georgiou, Niki
    Kyriacou, Efthyvoulos
    Avraamides, Costantinos
    Martin, Richard M.
    INTERNATIONAL ANGIOLOGY, 2022, 41 (06) : 492 - 499
  • [29] Adding ethnicity to cardiovascular risk prediction: external validation and model updating of SCORE2 using data from the multiethnic HELIUS population cohort
    Van Apeldoorn, J. A. N.
    Hageman, S. H. J.
    Harskamp, R. E.
    Agyemang, C.
    van den Born, B. J. H.
    Van Dalen, J. W.
    Galenkamp, H.
    Richard, E.
    Valkengoed, I. G. M.
    Visseren, F. L. J.
    Dorresteijn, J. A. N.
    Van Charante, E. P. Moll
    EUROPEAN HEART JOURNAL, 2024, 45
  • [30] SCORE2 Assessment in The Calculation of Cardiovascular Risk in Patients with Rheumatoid Arthritis (vol 11, 2363, 2021)
    Ferraz-Amaro, Ivan
    Corrales, Alfonso
    Atienza-Mateo, Belen
    Vegas-Revenga, Nuria
    Prieto-Pena, Diana
    Sanchez-Martin, Julio
    Almeida, Cristina
    Quevedo-Abeledo, Juan Carlos
    Blanco, Ricardo
    Gonzalez-Gay, Miguel A.
    DIAGNOSTICS, 2022, 12 (02)